Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dornase Alfa for Subarachnoid Hemorrhage (RESET)
NCT06723717Phase 2Recruiting
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dornase alfa in subarachnoid hemorrhage (SAH), delayed cerebral ischemia (DCI), sponsored by Adolphe de Rothschild Foundation Hospital. Started Sep 2025; status: recruiting.
02
Drugs
dornase alfa
03
Conditions
subarachnoid hemorrhage (SAH)delayed cerebral ischemia (DCI)
Beyond the preview
Go deeper on NCT06723717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723717.